Table 1.
Descriptive Statistics
| Study | Country | N | Year | Age Range | Personality Scale | Follow up Mean (Max) | Diabetes % Base (Follow up) | HBP % Base (Follow up) | Heart % Base (Follow up) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BASE-II | Germany | 1,437 | 2009 | 21–84 | BFI-S | 4.17 | (5) | 7% | (4%) | 36% | (15%) | 10% | (6%) |
| EAS | U.S. | 734 | 2005 | 69–99 | IPIP-50 | 3.94 | (11) | 19% | (17%) | 66% | (22%) | 37% | (15%) |
| ELSA | U.K. | 6263 | 2002 | 29–99 | MIDI | 3.89 | (5) | 8% | (4%) | 39% | (11%) | 18% | (8%) |
| HRS | U.S. | 18,925 | 2006 | 25–105 | MIDI | 5.19 | (9) | 20% | (8%) | 55% | (23%) | 22% | (12%) |
| ILSE | Germany | 478 | 1994 | 60–64 | NEO-FFI | 11.37 | (13) | 11% | (4%) | 42% | (14%) | 41% | (32%) |
| LBC1936 | U.K. | 959 | 2006 | 67–71 | IPIP | 6.53 | (12) | 8% | (7%) | 40% | (12%) | 24% | (13%) |
| LBLS | U.S. | 935 | 1994 | 30–97 | NEO-PI-R | 9.00 | (9) | 10% | (58%) | 46% | (51%) | - | - |
| MAP | U.S. | 604 | 1997 | 56–97 | NEO-FFI | 8.41 | (14) | 14% | (10%) | 54% | (30%) | 10% | (8%) |
| MAS | Australia | 860 | 2005 | 70–91 | NEO-PI-R | 5.81 | (9) | 12% | (4%) | 61% | (35%) | 35% | (13%) |
| MIDUS | U.S. | 5,988 | 1994 | 20–75 | MIDI | 11.54 | (19) | 5% | (12%) | 14% | (52%) | 11% | (11%) |
| NAS | U.S. | 820 | 1990 | 47–85 | Goldberg | 14.10 | (26) | 11% | (5%) | 41% | (18%) | 23% | (13%) |
| OATS | Australia | 463 | 1997 | 65–90 | NEO-PI-R | 3.74 | (9) | 10% | (3%) | 52% | (17%) | 25% | (7%) |
| ROS | U.S. | 1,326 | 1994 | 55–103 | NEO-FFI | 9.10 | (23) | 13% | (11%) | 45% | (37%) | 10% | (7%) |
| SLS | U.S. | 876 | 2001 | 29–100 | NEO-PI-R | 6.98 | (7) | 18% | 46% | (30%) | 72% | - | |
| WLS | U.S. | 10,560 | 1993 | 33–75 | BFI | 18.00 | (18) | 4% | (13%) | 23% | (46%) | 7% | (19%) |